[Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery].
Two patients with advanced gastric cancer who underwent gastrectomy and pathological examination were both diagnosed as having Stage IV gastric cancer with distant lymph-node metastases and peritoneal dissemination, respectively. The patients received S-1 and low-dose CDDP in combination therapy after reduction surgery. Each treatment course consisted of S-1 100 mg/body oral administration for 3 weeks and intravenous administration of CDDP at a dose of 25 mg/m(2) on days 7, 14 and 21. The course repeated after a two-week rest period, and the treatment was repeated every five weeks. After three courses of treatment, both patients received S-1 100 mg/body for 2 weeks on and 2 weeks off as long as possible. They remain alive 15 and 12 months after initial treatment, respectively, without any sign of recurrence. The patients did not experience grade 3 or more adverse events and received this regimen as an outpatient. These results suggest that combination therapy with S-1 and low-dose CDDP is effective against advanced gastric cancer.
Sugie
Tomoharu
T
Dept. of Surgery, Kyoto Police Hospital.
Nagai
Toshihiro
T
Ohgaki
Kazuhisa
K
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin